



Universiteit  
Leiden  
The Netherlands

## Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis

Kooloos, W.M.

### Citation

Kooloos, W. M. (2009, December 9). *Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis*. Retrieved from <https://hdl.handle.net/1887/14497>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14497>

**Note:** To cite this publication please use the final published version (if applicable).



Potential role of pharmacogenetics for optimization of drug therapy in rheumatoid arthritis

© W.M. Kooloos, 2009

ISBN: 978-90-9024834-9

Graphic design: Sander van der Steen (cover)

Printed by: Proefschriftmaken.nl || Printyourthesis.com

Published by: Uitgeverij BOXPress, Oisterwijk

The research presented in this thesis was performed at the Department of Clinical Pharmacy & Toxicology of Leiden University Medical Center, Leiden, The Netherlands. The research was financially supported by the foundation Nuts Ohra (Amsterdam).

The printing of this thesis was financially supported by:

AZL Onderzoeks- en Ontwikkelingskrediet

# **Potential role of pharmacogenetics for optimization of drug therapy in rheumatoid arthritis**

## **Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 9 december 2009  
klokke 11.15 uur  
door

**Wouter Michiel Kooloos**

geboren te Leiderdorp  
op 14 december 1982

**Promotores**

Prof. Dr. H.-J. Guchelaar

Prof. Dr. T.W.J. Huizinga

**Copromotores**

Dr. J.A.M. Wessels

**Promotiecommissie**

Dr. J.T. den Dunnen

Prof. Dr. A.C.G. Egberts

Prof.Dr. P.L.C.M. van Riel

# Contents

<b>Chapter 1:</b>	General Introduction and Outline	7
<i>Part I: Methotrexate</i>		
<b>Chapter 2:</b>	Pharmacogenetics of methotrexate in rheumatoid arthritis	19
<b>Chapter 3:</b>	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.	31
<b>Chapter 4</b>	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis	49
<b>Chapter 5</b>	Cross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established RA	67
<b>Chapter 6</b>	Validation of the clinical pharmacogenetic model by predicting MTX monotherapy efficacy in a Swedish Cohort of patients with recent-onset rheumatoid arthritis	81
<b>Chapter 7</b>	The influence of the number of haplotypes of MTHFR 1298A-677C alleles on the predicted probability to respond to methotrexate in early RA patients	93
<i>part II: Adalimumab</i>		
<b>Chapter 8</b>	Pharmacogenetics of TNF inhibitors in rheumatoid arthritis	105
<b>Chapter 9</b>	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case-study	119
<b>Chapter 10</b>	Pharmacogenetics of adalimumab in RA: genetic variants related to mechanism of action of TNF inhibitors	135
<b>Chapter 11</b>	Summary	149
<b>Chapter 12</b>	General discussion and future perspectives	153
<b>Nederlandse samenvatting</b>		171
<b>List of publications</b>		177
<b>Nawoord</b>		178
<b>Curriculum Vitae</b>		179

